The Defeat-NCD Partnership

Scaling up action on NCDs

The Defeat-NCD Partnership was established in January 2018 to help tackle the most significant global health challenge of the century: premature death, sickness and disability from the associated social and economic impacts of certain non-communicable diseases (NCDs).

 

Partnering across sectors

The public–private–people partnership is hosted by the United Nations Institute for Training and Research (UNITAR) and includes governments, multilateral agencies, civil society, academia, philanthropic foundations and the private sector.

At an official launch event during the UN General Assembly on 24 September, Novo Nordisk announced its commitment to the Partnership.

 

Urgent need for action

NCDs are the leading cause of death and disability globally, accounting for 71% of all deaths in 2016.1 An increasing number of these deaths occur in low-resource countries, affecting adults at a younger age.1

Each year, 15 million people between the ages of 30 and 69 die prematurely from an NCD. More than 85% of these premature deaths occur in low- and middle-income countries.1

 

Focus

The Partnership will initially focus on diabetes and hypertension. Both conditions are closely related and contribute significantly to the burden of premature mortality and disability from NCDs.2,3 Subsequently, the Partnership will address other NCDs of major prevalence and impact such as certain cancers and lung conditions.

The Partnership will drive action across four key areas:

  • NCD National capacity building: Help governments to strengthen key institutions and develop plans of action
  • NCD Community health scale-up: Increase the provision of NCD services through community action and health system strengthening
  • NCD Marketplace: Expand the consistent availability of affordable essential medicines, diagnostics, and technologies for NCDs
  • NCD Financing: Support low-resource countries in securing financing to achieve universal health coverage for NCDs

 

Download partnership brochure

Visit the Defeat-NCD Partnership website 

 


Learn more

Scaling up action on NCDs

A blogpost by Novo Nordisk's CEO: Why the launch of Defeat-NCD is a defining moment in the fight against NCDs 

View the blogpost

 

The launch of the Defeat-NCD partnership

The Danish Government and Novo Nordisk are the first to partner with the new Defeat-NCD initiative

View the video

 


References:

1. World Health Organization. Noncommunicable Diseases. Fact sheet. 2018; www.who.int/mediacentre/factsheets/fs355/en/. Accessed 2 July, 2018.

2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403-418.

3. Parving H-H, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes. British medical journal (Clinical research ed). 1988;296(6616):156.